Drugs / HTMC0658
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07174115 | Aug 2025 → Apr 2026 overdue | chronic rhinosinusitis | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTMC0658 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07174115 ↗ |
| Route | Oral | “orally” NCT07174115 ↗ |